Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | TYK2 | P29597 | 3/20 | 0.32 |
| ▸ | JAK3 | P52333 | 3/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117086 | 0.84 | JAK2 (0.38) | JAK2JAK1TYK2JAK3CYP2D6 | |
| Hydrochloric Acid SCHEMBL5390694 | 0.82 | JAK2 (0.37) | JAK2JAK1TYK2JAK3CYP2D6 | |
| SCHEMBL28751639 | 0.80 | ADH1B (0.41) | JAK2JAK1TYK2JAK3CYP2D6 | |
| SCHEMBL5360130 | 0.79 | KCNH3 (0.37) | KCNH3 | |
| SCHEMBL4120441 | 0.78 | ADH1B (0.45) | CYP2D6 | |
| Hydrochloric Acid SCHEMBL5394673 | 0.78 | ADH1B (0.40) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL28707592 | 0.76 | NPC1 (0.34) | KCNH3 | |
| SCHEMBL28722473 | 0.75 | JAK2 (0.34) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL16480078 | 0.75 | SAT1 (0.35) | CNR2JAK2JAK1TYK2JAK3 | |
| SCHEMBL28722472 | 0.75 | JAK2 (0.34) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2026-05-05 | — | — | US | disclosed |
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2024-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059690-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | SIGMAR1, OPRD1, P2RX3 | CNR2 181/4885JAK2 1700/4885JAK1 1002/4885 |
| US-12617797-B2 | Substituted pyrazolo [1,5-a]pyrimidines having multimodal activity against pain | SIGMAR1, OPRD1, OPRL1 | CNR2 16/4885JAK2 3056/4885JAK1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.